4-Antibody appoints new CEO
This article was originally published in Scrip
Swiss biopharma company 4-Antibody AG has appointed Dr Robert F Burns as chief executive officer. Dr Burns will drive multi-target pharma collaborations, a key goal for the company following its deal with Boehringer Ingelheim last March, whereby it will develop fully human antibodies for a number of targets in a variety of disease indications. Dr Burns previously served as CEO at both human antibody therapeutics research company Affitech A/S and biotech company Celldex Therapeutics.